New therapeutic option for irritable bowel syndrome: Serum-derived bovine immunoglobulin

Table 2 Presentation of irritable bowel syndrome patients with constipation

Patient No./age (yr)/gender	Primary symptoms	Comorbidity	Other GI therapy	SBI therapy/duration	Outcome
IBS-C 1/22/F	Constipation, bloating,	None	Low FODMAP diet,	Discontinued after 11 wk	Ineffective
	distension		linaclotide,
			lubiprostone
IBS-C 2/55/F	Bloating,	Non-erosive reflux disease	lubiprostone	Ongoing	Reduced bloating and distension,
	distension,			14 wk	obstipation unchanged
	nausea,
	obstipation

IBS-C: Irritable bowel syndrome with constipation; SBI: Serum-derived bovine immunoglobulin; GI: Gastrointestinal.